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 Introduction 
 Molecular or ‘targeted’ therapy is considered to be a 
new strategy in medical oncology, supplementing the tra-
ditional options surgery, irradiation, and chemotherapy. 
To qualify as targeted therapy, three requirements should 
be met: the target should be an important metabolic path-
way, it should be measurable, and interaction with the 
target should result in clinical benefit  [1] . Targeted ther-
apy differs from traditional antineoplastic chemotherapy 
in several ways. It has a different toxicity profile (less se-
vere side effects, different spectrum, frequently rash or 
hand-foot syndrome). Most small-molecule agents can be 
given orally and interact with one or more molecular tar-
gets, usually involved in cellular signalling pathways. 
Treatment with these agents results in a different re-
sponse pattern (stabilization of disease rather than mea-
surable remission). Often, there is no clearly defined 
dose-response relationship. The proof of specific target 
expression, for instance by immunohistochemistry, en-
ables an individualized treatment, sparing the treatment 
side effects in patients not expressing the target molecule 
 [2–7] .
 Several approaches can be used for the interaction with 
target molecules in genito-urinary cancer treatment. 
These may consist of competitive inhibition (example: 
atrasentan, an endothelin receptor antagonist), antibody 
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 Abstract 
 During recent years, significant advances have been made 
in the field of molecular therapy in urologic oncology, main-
ly for advanced renal cell carcinoma. In this hitherto largely 
treatment-refractory disease, several agents have been de-
veloped targeting the von Hippel-Lindau metabolic path-
way which is involved in carcinogenesis and progression of 
the majority of renal cell carcinomas. Although cure may not 
be expected, new drugs, such as the multikinase inhibitors 
sorafenib and sunitinib and the mammalian target of rapa-
mycine inhibitor temsirolimus, frequently stabilize the dis-
ease course and may improve survival. Fewer data are avail-
able supporting molecular therapies in prostate, bladder, 
and testicular cancers. Preliminary data suggest a potential 
role of high-dose calcitriol and thalidomide in hormone-re-
fractory prostate cancer, whereas targeted therapies in blad-
der and testicular cancers are still more or less limited to sin-
gle-case experiences. The great theoretical potential and 
the multitude of possible targets and drug combinations, 
however, support further research into this exciting field of 
medical treatment of urologic malignancies. 
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binding to a ligand (example: bevacizumab, an antibody 
against vascular endothelial growth factor; VEGF), anti-
body binding to a receptor (example: trastuzumab, an an-
tibody against Her2; ErbB2), inhibition of the receptor ty-
rosine kinase (example: gefitinib, an inhibitor of the re-
ceptor of epidermal growth factor; EGF), inhibition of 
tyrosine kinases in the downstream signalling pathway 
(example: temsirolimus, an inhibitor of mammalian tar-
get of rapamycin; mTOR), or application of a ligand to a 
receptor (example: calcitriol, binding to the calcitriol re-
ceptor). During recent years, several targeted treatment 
strategies have been evaluated in urologic oncology, with 
differing success. Some of them offer a treatment option 
in hitherto almost untreatable disease states and might 
become a new standard of care in the years ahead. In this 
article, we summarize the currently available targeted 
treatment options in urologic oncology. In the rapidly 
growing field of molecular therapy, we focused on thera-
pies with proven or probable value in clinical practice.
 Renal Cell Carcinoma 
 In the field of urologic oncology, the greatest body of 
evidence is available supporting targeted therapy of ad-
vanced renal cell carcinoma. This disease is notoriously 
resistant to conventional chemotherapy and radiothera-
py and is, therefore, particularly difficult to treat, when 
surgery was unable to control the disease. The majority 
of clear cell renal cell carcinomas, the by far most com-
mon type of kidney cancer, harbour a loss of function of 
the von Hippel-Lindau gene product (chromosome 3p 
deletion, suppressed expression or inactivating muta-
tions of the gene). In normal tissue, the von Hippel-Lin-
dau protein is involved in the regulation of responses to 
hypoxia  [2, 4] .  Figure 1 illustrates the signalling pathway 
activated by the loss of function of this gene  [2, 8] . Sev-
eral targeted therapies have shown clinical activity in re-
nal cell carcinomas. Molecular treatment may target the 
ligand of the VEGF receptor (bevacizumab is a monoclo-
nal antibody against VEGF receptor), receptor tyrosine 
kinases VEGF receptor and platelet-derived growth fac-
tor (PDGF) receptor (sunitinib and sorafenib target these 
receptors), or it may intervene in the downstream signal-
ling pathway (temsirolimus is an inhibitor of the mTOR, 
a serine-threonine protein kinase involved in the down-
stream signalling pathway). Besides its inhibitory effect 
on receptor tyrosine kinases, the multikinase inhibitor 
sorafenib also interacts with the downstream signalling 
cascade by inhibiting the serine-threonine Raf-1 kinase 
 [2, 9–11] . The majority of renal cell carcinomas overex-
press the EGF receptor and/or the receptor tyrosine ki-
nase ErbB2 (Her2). Both receptor tyrosine kinases may 
be inhibited by lapatinib  [9, 12] .
 At present, of all targeted therapies, the greatest body 
of evidence is probably available supporting the clinical 
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 Fig. 1. The von Hippel-Lindau pathway in 
renal cell carcinoma. Non-functioning von 
Hippel-Lindau gene product (VHL pro-
tein, hatched) results in decreased binding 
and cleavage of hypoxia-inducible factor 
alpha (HIF-  ), subsequent transfer of HIF-
  into the nucleus, and binding to HIF-  , 
leading to the transcription of the growth 
factors vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor 
(PDGF). The secreted growth factors bind 
to their receptors (vascular endothelial 
growth factor receptor, VEGFR, and plate-
let-derived growth factor receptor, PDG-
FR) in an autocrine and paracrine manner, 
causing dimerization and autophosphory-
lation of the transmembrane receptor pro-
tein kinases and activation of downstream 
signalling pathways (flashs), causing tu-
mour cell and vascular endothelial and 
stromal proliferation. Data derived from 
Patel et al.  [2] and Rini and Small  [8] . 
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tinib as a second-line treatment after failure of cytokine-
based first-line therapy produced a high rate of partial 
remissions  [13] . In a randomized trial comparing suni-
tinib with interferon alpha as first-line treatments for 
metastatic renal cell carcinoma  [14] , the median progres-
sion-free survival was significantly longer in patients re-
ceiving sunitinib than in those receiving interferon alpha 
(11 vs. 5 months). The response rate was higher in the 
sunitinib group than in the interferon alpha group (31 vs. 
6%, p  ! 0.001). There was a trend towards an increased 
overall survival in the sunitinib arm; the significance lev-
el set for the interim analysis was, however, not reached 
 [14] . An example for a partial remission seen during first-
line treatment with sunitinib is shown in  figure 2 .
 For sorafenib, mature data from randomized trials are 
not yet available for the first-line setting. Data from a sec-
ond-line trial performed in patients progressing during 
initial systemic treatment  [15] , however, indicate that this 
substance has also a promising activity in metastatic renal 
cell carcinoma. As compared with placebo, the median 
progression-free survival was longer in patients receiving 
sorafenib (5.5 vs. 2.8 months, p  ! 0.001), and the partial 
response rate was also higher with sorafenib (10 vs. 2%,
p  ! 0.001). As with the first-line sunitinib trial  [14] , there 
was a tendency towards an improved overall survival that 
did not fit the required significance threshold for the in-
terim analysis  [15] . Sorafenib and sunitinib have a favour-
able side effect profile, with rash and diarrhoea occurring 
most commonly. Sorafenib treatment harbours a small 
risk of developing coronary heart disease and myocardial 
infarction which, however, seems to be outweighed by the 
clinical benefit of the drug  [14, 15] .
 Bevacizumab is a monoclonal antibody binding and 
inactivating VEGF, thus potentially developing anti-an-
giogenic and antitumour activities in renal cell carci-
noma. This agent was the first molecular therapy show-
ing clinical activity in metastatic renal cell carcinoma in 
a randomized trial  [16] . As compared with placebo, 
high-dose bevacizumab (10 mg/kg every 2 weeks) sig-
nificantly delayed progression in patients with meta-
static clear cell renal cell carcinoma with progression 
during prior cytokine treatment or contra-indications 
to such treatment. There was, however, no effect on sur-
vival  [16] .
 Blockage of the mTOR serine-threonine protein ki-
nase (as a part of downstream signalling pathways) is an-
other promising molecular treatment in metastatic renal 
cell carcinoma. In a phase 3 trial  [17] , 626 patients with 
high-risk metastatic renal cell carcinoma were random-
ized into three arms: interferon alpha (up to 18 million U 
s.c. three times a week) versus the mTOR inhibitor tem-
sirolimus (25 mg i.v. once a week) versus temsirolimus (15 
mg i.v. once a week) plus interferon alpha (6 million U s.c. 
three times a week). The median survival was signifi-
cantly longer in the 25-mg temsirolimus arm as com-
pared with the interferon alpha arm (10.9 vs. 7.3 months, 
p = 0.0069), whereas the lower dose combined with inter-
feron alpha was less effective (median survival 8.4 months, 
not significantly different from the interferon alpha arm). 
The toxicity profile was acceptable and was not apprecia-
bly different in the treatment arms  [17] .
prior to treatment  
after treatment 
a
b
 Fig. 2. Partial remission and reduced vascularization of a liver 
metastasis of a clear-cell renal cell carcinoma (arrowheads) in a 
75-year-old woman after one cycle of sunitinib.  a Before treat-
ment.  b After treatment. 
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in a randomized phase 3 trial in 417 patients with meta-
static renal cell carcinoma – 94% had received cytokine 
therapy, lapatinib dose 1,250 mg daily; control arm: hor-
monal treatment  [12] . Whereas there was no detectable 
overall survival difference in the whole study population 
(median 46.9 weeks for lapatinib vs. 43.1 weeks for hor-
monal treatment, p = 0.29), the overall survival was sig-
nificantly improved by lapatinib treatment in the sub-
group (56%) of the patients whose tumour overexpressed 
EGF receptor proven by immunohistochemistry (median 
46.0 weeks for lapatinib vs. 37.9 weeks for hormonal treat-
ment, p = 0.02). The patients with EGF receptor-overex-
pressing tumours apparently had a particularly poor sur-
vival when treated with hormonal therapy; this survival 
disadvantage seemed to be compensated by application 
of lapatinib. The toxicity was moderate with rash and di-
arrhoea, each affecting about 40% of the patients receiv-
ing lapatinib  [12] .
 Although many molecular treatments have shown sin-
gle-agent activity in renal cell carcinoma, complete re-
missions are extremely rare, and all patients are deemed 
to eventually progress and succumb to their malignancy. 
To improve response rates and survival or even to cure 
some patients, the combination of different molecular in-
terventions is a tantalizing strategy. Molecular agents 
may be combined as ‘horizontal blockade’ in the case of 
simultaneous inhibition of different receptors (for in-
stance VEGF and PDGF receptors by sunitinib or 
sorafenib plus EGF receptor by erlotinib or lapatinib) or 
as ‘vertical blockade’ by intervention at more than one 
level in the same pathway (for instance bevacizumab plus 
sorafenib or lapatinib plus temsirolimus). However, such 
interventions harbour the risk of surprising and signifi-
cant toxicity and require careful investigations in con-
trolled trials. There are first promising results from com-
bined treatment approaches available. Partial responses 
were observed by combined sorafenib and bevacizumab 
treatment even in patients with the sarcomatoid variant 
of renal cell carcinoma which is a highly aggressive sub-
type with a particularly poor prognosis  [18] . The ob-
served toxic effects were, however, considerable  [19] .
 There is no consensus on the necessity of nephrectomy 
prior to molecularly targeted therapy for metastatic renal 
cell carcinomas. Most patients in randomized trials dem-
onstrating efficacy of targeted therapy for renal cell car-
cinoma underwent nephrectomy initially. There is, how-
ever, still no evidence that nephrectomy improves the 
survival in this setting, as it did in patients subsequently 
receiving cytokines  [20] .
 Prostate Cancer 
 Docetaxel-based chemotherapy is an active treatment 
in patients with hormone-refractory prostate cancer. It 
has been shown to improve the median survival by ap-
proximately 2 months as compared with treatment with 
mitoxantrone plus prednisolone  [21] . Two substances 
tested combined with docetaxel-based chemotherapy 
showed promising results in this setting. Although the 
precise mechanism of action of thalidomide is still un-
known  [4] , it may be regarded as a ‘targeted’ cancer treat-
ment because of its anti-angiogenic and immunomodula-
tory properties. In a small randomized trial comparing 
weekly docetaxel (30 mg/m 2  for 3 weeks of a 4-week cycle) 
with or without thalidomide (200 mg daily) [22, 23] , the 
median survival was better in the thalidomide group 
(25.9 vs. 14.7 months, p = 0.04). This surprisingly high 
survival advantage contrasts favourably with the 2-month 
median survival gained by docetaxel treatment as com-
pared with mitoxantrone plus prednisolone and calls for 
further evaluation of this regimen in patients with hor-
mone-refractory prostate cancer.
 The calcitriol receptor is another target with promis-
ing clinical potential in prostate cancer. Experimental in 
vitro and in vivo models suggest that calcitriol may in-
duce apoptosis and inhibit tumour growth and metastat-
ic spread  [24] . In an interim analysis of a double-blind 
randomized trial comparing high-dose calcitriol with 
placebo in combination with weekly docetaxel (36 mg/m 2  
for 3 weeks of a 4-week cycle)  [25] , patients receiving cal-
citriol had an improved overall survival. The difference 
just reached significance level in multivariate analysis
(p = 0.035), but missed it narrowly in univariate analysis 
(p = 0.07). There was only a marginal difference in pros-
tate-specific antigen response rates. High-dose calcitriol 
had a favourable safety profile  [25] .
 Endothelin-1 is secreted by prostate cancer cells and 
promotes tumour growth and metastatic spread by auto-
crine and/or paracrine activity. It has been found to stim-
ulate the mitotic activity in osteoblasts and to decrease 
osteoclastic bone resorption and osteoclast motility, thus 
promoting the development of osteoblastic bone metas-
tases  [26] . Besides some symptomatic improvement and 
biochemical responses of prostate-specific antigen and 
bone turnover markers, however, the clinical benefit of 
single-agent treatment with the endothelin-1 antagonist 
atrasentan is limited. In a meta-analysis of more than 
1,000 patients with hormone-refractory prostate cancer 
 [27] , there was only a marginal difference from placebo 
concerning disease progression. A possible role of atrasen-
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patients with bone involvement, needs further evaluation 
in controlled trials. Based on the available clinical data, 
approval for atrasentan was not granted by the Food and 
Drug Administration  [26] .
 Up to now, clinical trials investigating tyrosine kinase 
inhibitors or monoclonal antibodies as monotherapy for 
hormone-refractory prostate cancer yielded uniformly 
disappointing results  [28–31] .
 Bladder Cancer 
 The molecular pathways involved in carcinogenesis 
and progression of invasive bladder cancer are increas-
ingly well understood. There are several exciting options 
to intervene in these pathways in preclinical and clinical 
testing  [32] . Up to now, however, there are still only a few 
reports on clinically meaningful benefits of molecular 
treatment in bladder cancer. Invasive bladder cancer cells 
express the receptor tyrosine kinases EGF and Her2 
( fig. 3 ). Inhibition solely of the EGF receptor with gefi-
tinib was without appreciable additional effect in combi-
nation chemotherapy with gemcitabine-cisplatin  [33] . 
Lapatinib inhibits both EGF and Her2 receptor tyrosine 
kinases and has shown promising activity in advanced 
breast cancer  [34] . In one study  [35] , patients with ad-
vanced urothelial carcinoma and immunohistochemical 
evidence of either EGF receptor and/or Her2 receptor 
overexpression who progressed after cisplatin-based 
first-line chemotherapy received 1,250 mg lapatinib daily 
as monotherapy. There were no complete and only one 
(although marked) partial remission by independent ra-
diological review. However, patients with strong expres-
sion of one or both markers seemed to benefit from the 
treatment in terms of stabilization of the disease. The tox-
icity was mild, with diarrhoea and rash representing the 
most common side effects  [35] .
 Testicular Cancer 
 Although a majority of seminomas and a subset of 
non-seminomas express c-kit  [36] , identifying them as 
potential candidates for imatinib treatment, there are no 
published reports on successful imatinib application in 
refractory germ cell tumours up to now. Among 6 pa-
tients with incurable chemotherapy-refractory germ cell 
tumours with c-kit expression (no difference between 
seminomas and non-seminomas was made), only 1 pa-
tient experienced transient stabilization of disease and 
tumour marker decrease  [37] . A minority of refractory 
germ cell tumours overexpress Her2  [38] . In one case of 
a cisplatin-refractory germ cell tumour with Her2 ex-
pression, treatment with the monoclonal antibody trastu-
zumab resulted in disease remission  [39] . Leydig cell tu-
mours rarely cause metastatic disease that, however, is 
largely resistant to conventional treatment with chemo-
therapy or radiotherapy. Since Leydig cell tumours ex-
press PDGF, kit ligand, and their receptors, PDGF recep-
tor and c-kit, they are potential candidates for imatinib 
a
b
 Fig. 3. Immunohistochemical reactions demonstrating strong 
staining of the complete surface membrane for the receptor tyro-
sine kinases EGF(EGFR) ( a ) and Her2 (Her2neu) ( b ) in a primar-
ily metastatic urothelial carcinoma of the bladder in a 65-year-old 
woman. Original magnification  ! 40. 
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promising  [40] . Experimental treatment in a 76-year-old 
man with metastatic Leydig cell tumour was, however, 
without detectable effect  [41] .
 Other Urologic Malignancies 
 Due to the low frequency of other types of urologic 
cancers, there are only very sparse data on potentially 
beneficial molecular treatment strategies. In one study 
 [42] , a dramatic clinical improvement has been achieved 
by a combination of imatinib and thalidomide in a pa-
tient with chemotherapy-refractory recurrent undiffer-
entiated prostate sarcoma. Adrenal carcinomas might be 
attractive targets for molecular therapy  [43] ; there are, 
however, still no reports on clinical advances in this 
field.
 Conclusions 
 Molecular treatment is currently changing the stan-
dards of medical treatment of advanced renal cell carci-
nomas, a type of cancer with very limited non-surgical 
treatment options. Although much less data support tar-
geted therapy of other urologic malignancies, it is likely 
that new treatment options will become available in the 
years ahead. Besides single-agent regimens, the combina-
tion of anti-angiogenic drugs with conventional chemo-
therapy may be a field of possible future advances.
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